US20140273095A1 - Serum-Free Cell Culture Medium - Google Patents

Serum-Free Cell Culture Medium Download PDF

Info

Publication number
US20140273095A1
US20140273095A1 US14/211,245 US201414211245A US2014273095A1 US 20140273095 A1 US20140273095 A1 US 20140273095A1 US 201414211245 A US201414211245 A US 201414211245A US 2014273095 A1 US2014273095 A1 US 2014273095A1
Authority
US
United States
Prior art keywords
cell
protein
cell culture
ornithine
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/211,245
Other languages
English (en)
Inventor
Shadia Abike Oshodi
Amy S. JOHNSON
Shawn M. LAWRENCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140273095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to CN201480023485.4A priority Critical patent/CN105143444A/zh
Priority to SG10202107444XA priority patent/SG10202107444XA/en
Priority to JP2016502807A priority patent/JP6781039B2/ja
Priority to KR1020207028935A priority patent/KR102229380B1/ko
Priority to IL300911A priority patent/IL300911A/en
Priority to CA3135232A priority patent/CA3135232A1/en
Priority to BR122020021864-9A priority patent/BR122020021864B1/pt
Priority to US14/211,245 priority patent/US20140273095A1/en
Priority to CA3238123A priority patent/CA3238123A1/en
Priority to EA201591817A priority patent/EA037568B1/ru
Priority to KR1020157027270A priority patent/KR102166166B1/ko
Priority to CA3188491A priority patent/CA3188491A1/en
Priority to SG10201707153UA priority patent/SG10201707153UA/en
Priority to SG11201507072TA priority patent/SG11201507072TA/en
Priority to CA2906768A priority patent/CA2906768C/en
Priority to KR1020247014487A priority patent/KR20240065185A/ko
Priority to CA3238121A priority patent/CA3238121A1/en
Priority to EA202190326A priority patent/EA202190326A3/ru
Priority to NZ711935A priority patent/NZ711935B2/en
Priority to PCT/US2014/028501 priority patent/WO2014144198A1/en
Priority to KR1020217021749A priority patent/KR20210090732A/ko
Priority to EA202191602A priority patent/EA202191602A3/ru
Priority to KR1020227027409A priority patent/KR20220116571A/ko
Priority to MX2015013176A priority patent/MX357977B/es
Priority to MYPI2015702985A priority patent/MY175957A/en
Priority to KR1020217007530A priority patent/KR102278316B1/ko
Priority to BR112015022682-5A priority patent/BR112015022682B1/pt
Priority to AU2014227804A priority patent/AU2014227804B2/en
Priority to IL281515A priority patent/IL281515B2/en
Assigned to REGENERON PHARMACEUTICALS, INC. reassignment REGENERON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JOHNSON, AMY S., LAWRENCE, SHAWN M., OSHODI, SHADIA ABIKE
Publication of US20140273095A1 publication Critical patent/US20140273095A1/en
Priority to IL241195A priority patent/IL241195B/en
Priority to MX2021001859A priority patent/MX2021001859A/es
Priority to MX2021008627A priority patent/MX2021008627A/es
Priority to HK16101075.8A priority patent/HK1213289A1/zh
Priority to IL264499A priority patent/IL264499A/en
Priority to JP2019083625A priority patent/JP6944969B2/ja
Priority to AU2020200052A priority patent/AU2020200052B2/en
Priority to US16/742,695 priority patent/US11332771B2/en
Priority to US17/370,389 priority patent/US11970724B2/en
Priority to AU2021205088A priority patent/AU2021205088B2/en
Priority to JP2021132239A priority patent/JP2021180682A/ja
Priority to IL289724A priority patent/IL289724B2/en
Priority to US17/712,697 priority patent/US20220228187A1/en
Priority to AU2022211862A priority patent/AU2022211862A1/en
Priority to US17/882,224 priority patent/US20220372436A1/en
Priority to JP2022145754A priority patent/JP7429743B2/ja
Priority to JP2023189068A priority patent/JP2024001357A/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Definitions

  • the invention relates to media for the culturing of cells and for the production of recombinant proteins.
  • the invention specifically relates to serum-free media for the culturing of recombinant CHO cells for the production of protein biotherapeutics.
  • Cell culture media comprising serum or protein hydrolysate components (i.e., peptones and tryptones) have a long history of use in the production of recombinant proteins from cultured cells. These components contain growth factors and a wide variety of other uncharacterized elements beneficial to cell growth and culture. However, they also contain uncharacterized elements that reduce growth or otherwise negatively impact recombinant protein production. They can also be an unwelcome potential source of variability. Despite their drawbacks, the benefits of using sera and hydrolysates have outweighed some of the disadvantages and they have been widely used in many cell culture applications.
  • serum or protein hydrolysate components i.e., peptones and tryptones
  • Biopharmaceuticals are generally produced in mammalian cell culture, particularly CHO cell culture.
  • the presence of uncharacterized or partly characterized components in those cell cultures are highly undesirable for the manufacture of biopharmaceuticals for human use.
  • the use of such uncharacterized or partly characterized components not only introduces production and regulatory inconsistencies, it raises the possibility of viral or fungal infection of the production culture.
  • serum containing or hydrolysate-based media introduces downstream processing challenges.
  • concentration of a desired biopharmaceutical in culture is generally on the order of grams per liter.
  • the presence of serum and hydrolysates in media can add more than 10 g/L of uncharacterized peptides and proteins, which must be removed in subsequent processing steps.
  • Serum and hydrolysates can also introduce variability in the amount of metals and other trace elements in the media. The elimination of serum and hydrolysates from culture media therefore eliminates these variations and potential encumbrances to the production and processing of drug substance.
  • the benefits to using serum-free and hydrolysate-free media include reduction in cost, reduction in variablity between drug lots, and minimization of the risk of introducing adventitious agents from undefined and unrefined components. Furthermore, where media are defined and uniform between batch runs, qualifying runs to test new media batches against current media are likewise minimized.
  • media for culturing mammalian cells wherein the media are chemically-defined and free of sera and hydrolysates, or that are serum-free and contain low manageable levels of hydrolysates, and yet allow for healthy and robust cell growth and maintenance, and high-titer production of biopharmaceutical drug substance.
  • OS media cell culture media that is free of sera
  • OS media increases cell viability and density, reduces cell doubling time, and permits high titer protein production by those cells.
  • OS media that contains low or trace amounts of protein hydrolysates or is chemically defined (i.e., contains no protein hydrolysates) in particular provides restored cell viability and density, cell doubling time, and high titer protein production.
  • the invention provides a cell culture medium, which is serum-free and comprises at least 0.09 mM ⁇ 0.014 mM ornithine.
  • the ornithine is present in the medium at a concentration ranging from 0.09 ⁇ 0.014 mM to 0.9 ⁇ 0.14 mM, such as 0.09 ⁇ 0.014 mM, 0.3 ⁇ 0.05 mM, 0.6 ⁇ 0.09 mM, or 0.9 ⁇ 0.14 mM ornithine.
  • the medium also contains at least 0.20 ⁇ 0.03 mM putrescine.
  • the additional putrescine is at a concentration ranging from 0.20 ⁇ 0.03 mM to 0.714 ⁇ 0.11 mM, such as 0.20 ⁇ 0.03 mM, 0.35 ⁇ 0.06, or 0.714 ⁇ 0.11 mM putrescine.
  • the medium contains 7.5 g/L hydrolysate. In some embodiments, the medium is free of any hydrolysate.
  • the medium contains a base medium that is chemically defined, such as a custom formulation or a commercially available base medium.
  • the complete medium is chemically defined, free of sera and free of hydrolysate.
  • the medium which is at its useful concentration (i.e., 1 ⁇ ) contains at least 40 ⁇ 6 mM or at least 70 ⁇ 10.5 mM of a mixture of amino acids or amino acid salts. In one embodiment, the medium contains at least 40 mM of a mixture of amino acids. In this or another embodiment, the medium contains at least 70 mM of a mixture of amino acids.
  • the mixture of amino acids (with the notable exception of glutamine, which may be added back to the medium as a point of use addition) contains alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
  • the medium contains one or more fatty acids.
  • the medium contains a mixture of fatty acids (or fatty acid derivatives) and alpha tocopherol.
  • Fatty acids or fatty acid derivatives are selected from the group consisting of linoleic acid, linolenic acid, thioctic acid, oleic acid, palmitic acid, stearic acid, arachidic acid, acid, lauric acid, behenic acid, decanoic acid, dodecanoic acid, hexanoic acid, lignoceric acid, myristic acid, and octanoic acid.
  • the medium contains a mixture of nucleosides. In one embodiment, the medium contains adenosine, guanosine, cytidine, uridine, thymidine, and hypoxanthine.
  • the medium contains a mixture of salts.
  • Salts include divalent cations, such as calcium and magnesium.
  • the medium contains calcium chloride and magnesium sulfate.
  • Other salts may include those of phosphate.
  • the medium (1) contains 7.5 g/L of a hydrolysate, (2) is serum-free, (3) contains 0.09 ⁇ 0.014 mM, 0.3 ⁇ 0.05 mM, 0.6 ⁇ 0.09 mM, or 0.9 ⁇ 0.14 mM ornithine, (4) optionally additionally contains 0.20 ⁇ 0.03 mM, 0.35 ⁇ 0.06, or 0.714 ⁇ 0.11 mM putrescine, (5) contains at least about 40 mM or at least about 70 mM of a mixture of amino acids including alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, (6) contains tocopherol and a mixture of fatty acids, (7) contains a mixture of nucleosides including
  • the invention provides a method for cultivating cells in a cell culture medium, such as any embodiment of the medium described in the foregoing aspect.
  • the method employs the steps of propagating or maintaining a cell or cells in a medium that (1) contains 7.5 g/L hydrolysate, or no hydrolysate, (2) is free of sera, (3) contains ornithine at a concentration of at least 0.09 mM ⁇ 0.014 mM, (4) and optionally contains putrescine, such as at least 0.20 ⁇ 0.03 mM.
  • the cell or cells are mammalian cells, avian cells, insect cells, yeast cells, or bacteria cells.
  • the cells are mammalian cells useful in the production of recombinant proteins, such as CHO cells or the derivative CHO-K1.
  • the cells express a protein of interest, such as a biotherapeutic protein.
  • the biotherapeutic protein may be an antigen binding protein, which may contain an Fc domain.
  • the protein of interest is a receptor-Fc-fusion protein, such as an ScFv molecule or a trap molecule. Trap molecules include the VEGF trap and IL-1 Trap proteins.
  • the protein of interest is an antibody, such as a humanized monoclonal antibody, a bispecific antibody, or an antibody fragment.
  • the cells cultured according to this method have an average doubling time that is no more than 30 hours. In one embodiment, the cell doubling time is no more than 24 hours. In one embodiment, when compared to cell growth in media that contains less than 0.09 ⁇ 0.014 mM ornithine (or less than 0.09 ⁇ 0.014 mM ornithine and less than 0.2 ⁇ 0.03 mM putrescine), the cells grown according to this method have an average doubling time that is at least one third the doubling time of the comparator control culture.
  • the inclusion of ornithine alone or a combination of ornithine and putrescine in serum-free media allows cultured cells to reach a higher viable cell count density than without the inclusion of ornithine or the combination of ornithine and putrescine.
  • the cell culture is capable of attaining a viable cell count density that is at least 15% greater than a similar cell culture in a similar cell culture medium that contains less than 0.09 ⁇ 0.014 mM ornithine (or less than 0.09 ⁇ 0.014 mM ornithine and less than 0.2 ⁇ 0.03 mM putrescine).
  • the cell culture is capable of attaining a viable cell count density that is at least 3-fold greater than a similar cell culture in a similar cell culture medium that contains less than 0.09 ⁇ 0.014 mM ornithine (or less than 0.09 ⁇ 0.014 mM ornithine and less than 0.2 ⁇ 0.03 mM putrescine).
  • the method includes the step of adding one or more point-of-use additions to the cell culture medium.
  • the point-of-use addition is any one or more of NaHCO 3 , glutamine, insulin, glucose, CuSO 4 , ZnSO 4 , FeCl 3 , NiSO 4 , Na 4 EDTA, and Na 3 Citrate.
  • the method employs the step of adding each of the following point-of-use chemicals to the cell culture medium: NaHCO 3 , glutamine, insulin, glucose, CuSO 4 , ZnSO 4 , FeCl 3 , NiSO 4 , Na 4 EDTA, and Na 3 Citrate.
  • the point-of-use additions can be included in the medium at the outset.
  • the aspect provides a method for cultivating cells in a serum-free medium which contains (1) ornithine at either 0.09 ⁇ 0.014 mM, 0.3 ⁇ 0.05 mM, 0.6- ⁇ 0.09 mM, or 0.9 ⁇ 0.14 mM cell culture medium; (2) optionally additionally putrescine at either 0.20 ⁇ 0.03 mM, 0.35 ⁇ 0.06, or 0.714 ⁇ 0.11 mM; (3) at least about 40 mM or at least about 70 mM of a mixture of amino acids including alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; (4) tocopherol and a mixture of fatty acids; (6) a mixture of nucleosides including adeno
  • the cell culture is capable of attaining a viable cell count density that is at least 3-fold greater than a similar cell culture in a similar cell culture medium that contains less than 0.09 ⁇ 0.014 mM ornithine (or less than 0.09 ⁇ 0.014 mM ornithine and less than 0.2 ⁇ 0.03 mM putrescine).
  • the medium contains 7.5 g/L hydrolysate; and in another embodiment, free of hydrolysates.
  • the invention provides a method for producing a protein of interest by employing the steps of (1) introducing into a cell a nucleic acid sequence that encodes a protein of interest; (2) selecting a cell carrying that nucleic acid sequence; (3) culturing the selected cell in an embodiment of the serum-free cell culture medium described in the first aspect or according to any embodiment of the method described in the second aspect; and (4) expressing the protein of interest in the cell, wherein the protein of interest is secreted into the medium.
  • the cell used in the production of the protein is a mammalian cell capable of producing a biotherapeutic, such as CHO, 293, and BHK cell, or any derivatives of them.
  • the cell is a CHO cell, such as a CHO-K1 cell.
  • the protein of interest is an antigen binding protein.
  • the protein of interest is a protein that has an Fc domain. In some cases, those two proteins of interest may overlap, such as in the case of a receptor-Fc-fusion protein, an antibody, and a ScFv protein for example.
  • the protein of interest is an antibody, such as a human antibody or a humanized antibody, an antibody fragment, such as an Fab or F(ab′) 2 , a bispecific antibody, a trap molecule, such as a VEGF-Trap or an IL-1-Trap, an ScFv molecule, a soluble TCR-Fc fusion protein, or the like.
  • the protein of interest is capable of being produced at an average seven day titer that is at least 7% greater, at least 14% greater, at least 80% greater, at least two fold greater, or at least three fold greater than the average seven day titer produced by a similar cell in a serum-free cell culture medium that contains less than 0.09 ⁇ 0.014 mM ornithine (or less than 0.09 ⁇ 0.014 mM ornithine and less than 0.2 ⁇ 0.03 mM putrescine) (“non-OS” media).
  • the protein of interest is produced by (1) introducing into a CHO cell a nucleic acid sequence that encodes a protein of interest, such as an antibody or other antigen-binding protein; (2) selecting a cell carrying that nucleic acid sequence; (3) culturing the selected cell in a serum-free cell culture medium which contains (a) ornithine at either 0.09 ⁇ 0.014, 0.3 ⁇ 0.05 mM, 0.6 ⁇ 0.09 mM, or 0.9 ⁇ 0.14 mM; (b) optionally additionally putrescine at either 0.20 ⁇ 0.03 mM, 0.35 ⁇ 0.06, or 0.714 ⁇ 0.11 mM; (c) at least 40 mM or at least 70 mM of a mixture of amino acids including: alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline
  • OS medium ornithine, or a combination of ornithine and putrescine
  • peptide As used herein “peptide,” “polypeptide” and “protein” are used interchangeably throughout and refer to a molecule comprising two or more amino acid residues joined to each other by a peptide bond. Peptides, polypeptides and proteins may also include modifications such as glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, alkylation, hydroxylation and ADP-ribosylation. Peptides, polypeptides, and proteins can be of scientific or commercial interest, including protein-based drugs. Peptides, polypeptides, and proteins include, among other things, antibodies and chimeric or fusion proteins. Peptides, polypeptides, and proteins are produced by recombinant animal cell lines using cell culture methods.
  • heterologous polynucleotide sequence refers to nucleic acid polymers encoding proteins of interest, such as chimeric proteins (like trap molecules), antibodies or antibody portions (e.g., VH, VL, CDR3) that are produced as a biopharmaceutical drug substance.
  • the heterologous polynucleotide sequence may be manufactured by genetic engineering techniques (e.g., such as a sequence encoding a chimeric protein, or a codon-optimized sequence, an intronless sequence, et cetera) and introduced into the cell, where it may reside as an episome or be intergrated into the genome of the cell.
  • the heterologous polynucleotide sequence may be a naturally occurring sequence that is introduced into an ectopic site within the production cell genome.
  • the heterologous polypeptide sequence may be a naturally occurring sequence from another organism, such as a sequence encoding a human ortholog.
  • Antibody refers to an immunoglobulin molecule consisting of four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
  • Each heavy chain has a heavy chain variable region (HCVR or VH) and a heavy chain constant region.
  • the heavy chain constant region contains three domains, CH1, CH2 and CH3.
  • Each light chain has a light chain variable region and a light chain constant region.
  • the light chain constant region consists of one domain (CL).
  • the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the term “antibody” includes reference to both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass.
  • the term “antibody” includes antibody molecules prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell transfected to express the antibody.
  • the term antibody also includes bispecific antibody, which includes a heterotetrameric immunoglobulin that can bind to more than one different epitope. Bispecific antibodies are generally described in US Patent Application Publication No. 2010/0331527, which is incorporated by reference into this application.
  • an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen.
  • binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al.
  • an antibody or antigen-binding portion thereof may be part of a larger immunoadhesion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides.
  • immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov et al. (1995) Human Antibodies and Hybridomas 6:93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov et al. (1994) Mol. Immunol. 31:1047-1058).
  • Antibody portions such as Fab and F(ab′)2 fragments, can be prepared from whole antibodies using conventional techniques, such as via papain or pepsin digestion of whole antibodies. Moreover, antibodies, antibody portions and immunoadhesion molecules can be obtained using standard recombinant DNA techniques commonly known in the art (see Sambrook et al., 1989).
  • human antibody is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3.
  • the term “human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • recombinant human antibody is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial human antibody library, antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences.
  • Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences.
  • such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
  • Fc fusion proteins comprise part or all of two or more proteins, one of which is an Fc portion of an immunoglobulin molecule, which are not otherwise found together in nature. Preparation of fusion proteins comprising certain heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain) has been described, e.g., by Ashkenazi et al., Proc. Natl. Acad. ScL USA 88: 10535, 1991; Byrn et al., Nature 344:677, 1990; and Hollenbaugh et al., “Construction of Immunoglobulin Fusion Proteins”, in Current Protocols in Immunology, Suppl.
  • Receptor Fc fusion proteins comprise one or more extracellular domain(s) of a receptor coupled to an Fc moiety, which in some embodiments comprises a hinge region followed by a CH2 and CH3 domain of an immunoglobulin.
  • the Fc-fusion protein contains two or more distinct receptor chains that bind to a one or more ligand(s).
  • an Fc-fusion protein is a trap, such as for example an IL-1 trap (e.g., rilonacept, which contains the IL-1 RAcP ligand binding region fused to the IL-1R1 extracellular region fused to Fc of hIgG1; see U.S. Pat. No.
  • VEGF trap e.g., aflibercept, which contains the Ig domain 2 of the VEGF receptor Flt1 fused to the Ig domain 3 of the VEGF receptor Flk1 fused to Fc of hIgG1; see U.S. Pat. Nos. 7,087,411 and 7,279,159).
  • the present invention provides a serum-free medium that is useful in culturing cells and producing a biopharmaceutical drug substance.
  • “Serum-free” applies to a cell culture medium that does not contain animal sera, such as fetal bovine serum.
  • the serum-free media may contain 7.5 g/L of hydrolysates, such as soy hydrolysate.
  • the present invention also provides chemically defined media, which is not only serum-free, but also hydrolysate-free.
  • “Hydrolysate-free” applies to cell culture media that contains no exogenous protein hydrolysates such as animal or plant protein hydrolysates such, for example peptones, tryptones and the like.
  • chemically defined serum-free and low to no hydrolysate media requires additional ingredients to improve cell growth and protein production.
  • the cell culture media of the invention may be supplemented with additional ingredients such as polyamines or increased concentrations of components like amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements and the like, depending on the requirements of the cells to be cultured or the desired cell culture parameters.
  • the cell culture medium here is supplemented with ornithine, putrescine, or both (“OS media”) to improve cell growth, cell viability, and recombinant protein production.
  • the OS medium contains ornithine at a concentration (expressed in micromoles per liter) of at least about 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 540, 545, 550, 555, 560, 565, 568, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 620, 625, 630, 635, 640, 645, 650, 700, 750, 800, 850,
  • the media contains ornithine at a concentration of about 85, 90, 95, 100, 105, 110, 113, or 115 ⁇ M. In one embodiment, the medium contains 100 ⁇ M ⁇ 15 ⁇ M ornithine. In one embodiment, the medium contains 15 mg/L ⁇ 2.25 mg/L ornithine.HCl.
  • the media contains ornithine at a concentration of about 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, or 345 ⁇ M.
  • the medium contains 300 ⁇ M ⁇ 45 ⁇ M ornithine.
  • the medium contains 50 mg/L ⁇ 7.5 mg/L ornithine.HCl.
  • the media contains ornithine at a concentration of about 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, or 690 ⁇ M.
  • the medium contains 600 ⁇ M ⁇ 90 ⁇ M ornithine.
  • the medium contains 100 mg/L ⁇ 15 mg/L ornithine.HCl.
  • the media contains ornithine at a concentration of 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995, 1,000, 1,005, 1,010, 1,015, 1,020, 1,025, 1,030, or 1,035 ⁇ M.
  • the medium contains 900 ⁇ M ⁇ 135 ⁇ M ornithine.
  • the medium contains 150 mg/L ⁇ 22.5 mg/L ornithine.HCl.
  • Putrescine may optionally be added to the ornithine supplemented media.
  • Putrescine has been included, at very low concentrations, as a component in some cell culture media formulations; see for example WO 2005/028626, which describes 0.02-0.08 mg/L putrescine; U.S. Pat. No. 5,426,699 (0.08 mg/L); U.S. Pat. No. RE30,985 (0.16 mg/L); U.S. Pat. No. 5,811,299 (0.27 mg/L); U.S. Pat. No. 5,122,469 (0.5635 mg/L); U.S. Pat. No.
  • the media contains a combination of ornithine and putrescine, wherein the putrescine can be at a concentration of at least about 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 260, 365, 370, 375, 380, 385, 390, 395, 400, 405, or 410 ⁇ M.
  • the media contains putrescine at a concentration of about 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, or 230 ⁇ M. In one embodiment, the medium contains 200 ⁇ M ⁇ 30 ⁇ M putrescine in addition to 90 ⁇ M ⁇ 14 ⁇ M ornithine. In one embodiment, the medium contains 30 mg/L ⁇ 4.5 mg/L putrescine.2HCl in addition to 15 mg/L ⁇ 2.25 mg/L ornithine.HCl.
  • the media contains putrescine at a concentration of about 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, or 405 ⁇ M.
  • the medium contains 350 ⁇ M ⁇ 52.5 ⁇ M putrescine in addition to 90 ⁇ M ⁇ 14 ⁇ M ornithine.
  • the medium contains 57 mg/L ⁇ 8.55 mg/L putrescine.2HCl in addition to 15 mg/L ⁇ 2.25 mg/L ornithine.HCl.
  • the media contains putrescine at a concentration of about 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, or 805 ⁇ M.
  • the medium contains 714 ⁇ M ⁇ 105 ⁇ M putrescine in addition to 90 ⁇ M ⁇ 14 ⁇ M ornithine.
  • the medium contains 115 mg/L ⁇ 17.25 mg/L putrescine.2HCl in addition to 15 mg/L ⁇ 2.25 mg/L ornithine.HCl.
  • the media contains a pair-wise combination of any concentration of putrescine and ornithine listed above. In some embodiments, the media contains any pair-wise combination of about 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, or 805 ⁇ M putrescine, and about 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635,
  • the media in one embodiment contains about 700 ⁇ M putrescine plus any one of 510, 511, 512 ⁇ M, et sequens ornithine; or 701 ⁇ M putrescine plus any one of 510, 511, 512 ⁇ M, et sequens ornithine; et cetera.
  • the media in one embodiment contains about 600 ⁇ M ornithine plus any one of 700, 701, 702 ⁇ M, et sequens putrescine; or 601 ⁇ M ornithine plus any one of 700, 701, 702 ⁇ M, et sequens putrescine; et cetera.
  • the media contains 702 ⁇ M ⁇ 106 ⁇ M purescine+593 ⁇ M ⁇ 89 ⁇ M ornithine. In one particular embodiment, the media contains about 714 ⁇ M putrescine and 593 ⁇ M ornithine. In one embodiment, the media contains 115 mg/L ⁇ 17 mg/L putrescine.2HCl and 100 mg/L ⁇ 15 mg/L ornithine.HCl. In one particular embodiment, the media contains 115 mg/L putrescine.2HCl and 100 mg/L ornithine.HCl.
  • the media contains a mixture of nucleosides in a cumulative concentration of at least 50 ⁇ M, at least 60 ⁇ M, at least 70 ⁇ M, at least 80 ⁇ M, at least 90 ⁇ M, at least 100 ⁇ M, at least 110 ⁇ M, at least 115 ⁇ M, at least 120 ⁇ M, at least 125 ⁇ M, at least 130 ⁇ M, at least 135 ⁇ M, at least 140 ⁇ M, at least 145 ⁇ M, at least 150 ⁇ M, at least 155 ⁇ M, at least 160 ⁇ M, at least 165 ⁇ M, or at least 170 ⁇ M.
  • the media contains about 174 ⁇ M ⁇ 26 ⁇ M nucleoside.
  • the media contains purine derivatives in a cumulative concentration of at least 40 ⁇ M, at least 45 ⁇ M, at least 50 ⁇ M, at least 55 ⁇ M, at least 60 ⁇ M, at least 65 ⁇ M, at least 70 ⁇ M, at least 75 ⁇ M, at least 80 ⁇ M, at least 85 ⁇ M, at least 90 ⁇ M, at least 95 ⁇ M, at least 100 ⁇ M, or at least 105 ⁇ M.
  • the media contains about 106 ⁇ M ⁇ 5 ⁇ M of purine derivatives.
  • Purine derivatives include hypoxanthine and the nucleosides adenosine and guanosine.
  • the media contains pyrimidine derivatives in a cumulative concentration of at least 30 ⁇ M, at least 35 ⁇ M, at least 40 ⁇ M, at least 45 ⁇ M, at least 50 ⁇ M, at least 55 ⁇ M, at least 60 ⁇ M, or at least 65 ⁇ M.
  • the media contains about 68 ⁇ M ⁇ 5 ⁇ M of pyrimidine derivatives.
  • Pyrimidine derivatives include the nucleosides thymidine, uridine, and cytidine.
  • the media contains adenosine, guanosine, cytidine, uridine, thymidine and hypoxanthine.
  • the media also contains amino acids in a cumulative concentration of at least 40 mM, wherein the amount of glutamine is not included in the calculation of the cumulative total.
  • glutamine is not included in the media, but may be supplied as a “point-of-use addition” to the media during the culturing of cells such as during the production of protein.
  • the media may be supplemented with glutamine as a point-of-use addition.
  • glutamine is added in an amount less than about 40 mM, less than about 35 mM, less than about 30 mM, less than about 25 mM, less than about 20 mM, less than about 15 mM, less than about 10 mM, less than about 8 mM, less than about 7 mM, less than about 6 mM, less than about 5 mM, less than about 4 mM, less than about 3 mM, or less than about 2.5 mM.
  • the amount of glutamine in the media that was supplemented with glutamine is about 2 mM ⁇ 0.5 mM.
  • the media in addition to the inclusion of ornithine or a combination of both ornithine and putrescine, the media also contains amino acids having a non-polar side group in a concentration of at least 15 mM, at least 24 mM, at least 25 mM, at least 26 mM, at least 27 mM, at least 28 mM, at least 29 mM, or at least 30 mM. In one embodiment, the media contains about 30 mM of amino acids having a non-polar side group.
  • amino acids having non-polar side groups are amino acids having non-polar side groups.
  • about 42% ⁇ 1% by mole of the amino acids in the media are amino acids having a non-polar side group.
  • Amino acids having a non-polar side group include alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine.
  • the media in addition to the inclusion of ornithine or a combination of both ornithine and putrescine, the media also contains amino acids having an uncharged polar side group in a concentration of about 10 mM to 34 mM, about 11 mM to 33 mM, about 12 mM to 32 mM, about 13 mM to 31 mM, about 14 mM to 30 mM, about 15 mM to 29 mM, about 16 mM to 28 mM, about 17 mM to 27 mM, about 18 mM to 26 mM, about 19 mM to 25 mM, about 20 mM to 24 mM, about 21 mM to 23 mM, or about 22 mM.
  • the medium contains about 22 mM of amino acids having an uncharged polar side group. In another embodiment, the medium contains about 12 mM amino acids having an uncharged polar side group. In one embodiment, of the total amount by mole of amino acids contained within the media, about 14% to 46%, about 15% to 45%, about 16% to 44%, about 17% to 43%, about 18% to 42%, about 19% to 41%, about 20% to 40%, about 21% to 39%, about 22% to 38%, about 23% to 37%, about 24% to 36%, about 25% to 35%, about 26% to 34%, about 27% to 33%, about 28% to 32%, about 29% to 31%, or about 30% are amino acids having uncharged polar side groups.
  • amino acids having an uncharged polar side group include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the media in addition to the inclusion of ornithine or a combination of both ornithine and putrescine, the media also contains amino acids having a negative charge at pH 6 (i.e., acidic amino acids) in a concentration of about 4 mM to 14 mM, about 5 mM to 13 mM, about 6 mM to 12 mM, about 7 mM to 11 mM, about 8 mM to 10 mM, about 9 mM, or about 4 mM.
  • the media contains about 9 mM of acidic amino acids.
  • the media contains 9 mM ⁇ 1 mM of acidic amino acids.
  • acidic amino acids include aspartic acid and glutamic acid.
  • the media in addition to the inclusion of ornithine or a combination of both ornithine and putrescine, the media also contains amino acids having a positive charge at pH 6 (i.e., basic amino acids) in a concentration of at least 3.5 mM, at least 4 mM, at least 5 mM, at least 6 mM, at least 7 mM, at least 8 mM, at least 9 mM, at least 10 mM, or at least 11 mM.
  • the media contains about 11 mM of basic amino acids. In one embodiment, the media contains about 11.42 mM ⁇ 1 mM of basic amino acids.
  • At least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, or at least 15% are basic amino acids.
  • about 16% by mole of the amino acids in the media are basic amino acids.
  • about 15.8% ⁇ 2.4% by mole of the amino acids in the media are basic amino acids.
  • about 21% ⁇ 3.2% by mole of the amino acids in the media are basic amino acids.
  • Basic amino acids include lysine, arginine, and histidine.
  • the media in addition to the inclusion of ornithine or a combination of both ornithine and putrescine, the media also contains about 30 mM non-polar amino acids, about 22 mM uncharged polar amino acids, about 9 mM acidic amino acids, and about 11 mM basic amino acids.
  • the amino acids in the media about 42% by mole are non-polar amino acids, about 30% by mole are uncharged polar amino acids, about 13% by mole are acidic amino acids, and about 16% by mole are basic amino acids.
  • the media contains micromolar amounts of fatty acids (or fatty acid derivatives) and tocopherol.
  • the fatty acids include any one or more of linoleic acid, linolenic acid, thioctic acid, oleic acid, palmitic acid, stearic acid, arachidic acid, arachidonic acid, lauric acid, behenic acid, decanoic acid, dodecanoic acid, hexanoic acid, lignoceric acid, myristic acid, and octanoic acid.
  • the media contains tocopherol, linoleic acid, and thioctic acid.
  • the media also contains a mixture of vitamins, which includes other nutrients and essential nutrients, at a cumulative concentration of at least about 700 ⁇ M or at least about 2 mM.
  • the mixture of vitamins contains one or more of D-biotin, choline chloride, folic acid, myo-inositol, niacinamide, pyridoxine HCl, D-pantothenic acid (hemiCa), riboflavin, thiamine HCl, vitamin B12, and the like.
  • the mixture of vitamins includes all of D-biotin, choline chloride, folic acid, myo-inositol, niacinamide, pyridoxine HCl, D-pantothenic acid (hemiCa), riboflavin, thiamine HCl, and vitamin B12.
  • Various embodiments of the media of the invention include any of the combinations of the above described embodiments, including chemically defined, hydrolysate-free serum-free media comprising ornithine or putrescine in the indicated amounts, plus inter alia (a) amino acids; (b) optionally nucleosides; (c) salts of divalent cations; (d) fatty acids and tocopherol; and (e) vitamins.
  • all small amounts of hydrolysates may be added to the OS media.
  • Base media are generally known in the art and include inter alia Eagle's MEME (minimal essential media) (Eagle, Science, 1955, 112(3168):501-504), Ham's F12 (Ham, Proc. Nat'l. Acad. Sci. USA, 1965, 53:288-293), F-12 K medium, Dulbecco's medium, Dulbecco's Modified Eagle Medium (Proc. Natl. Acad. Sci.
  • Ventrex HL-1 media albumin-globulin media
  • albumin-globulin media Orr et al., Appl. Microbiol., 1973, 25(1):49-54
  • RPM I-1640 Medium RPMI-1641 Medium
  • Iscove's Modified Dulbecco's Medium McCoy's 5 A Medium
  • Leibovitz's L-15 Medium and serum-free media
  • serum-free media such as EX-CELLTM 300 Series (JRH Biosciences, Lenexa, Kans.), protamine-zinc-insulin media (Weiss et al., 1974, U.S. Pat. No.
  • the media is chemically defined and contains in addition to the ornithine or combination of both ornithine and putrescine: CaCl 2 2H 2 O; HEPES buffer, KCl; MgSO 4 ; NaCl; Na 2 HPO 4 or other phosphate salts; pyruvate; L-alanine; L-arginine HCl; L-asparagine H 2 O; L-aspartic acid; L-cysteine HCl H 2 O; L-glutamic acid; Glycine; L-histidine HCl H 2 O; L-isoleucine; L-leucine; L-lysine HCl; L-methionine; L-ornithine HCl; L-phenylalanine; L-proline; L-serine; L-threonine; L-tryptophan; L-tyrosine 2Na 2H 2 O; L-valine; D-biotin; cho
  • the starting osmolarity of the media of the invention is 200-500, 250-400, 275-350, or about 300 mOsm.
  • the osmolarity of the culture may increase up to about 350, 400, 450, or as high as 500 mOsm.
  • the osmolarity of the defined medium is less than about 300
  • the osmolarity is brought to about 300 with the addition of one or more salts in excess of the amount specified.
  • osmolarity is increased to a desired level by adding one or more of an osmolyte selected from sodium chloride, potassium chloride, a magnesium salt, a calcium salt, an amino acid salt, a salt of a fatty acid, sodium bicarbonate, sodium carbonate, potassium carbonate, a chelator that is a salt, a sugar (e.g., galactose, glucose, sucrose, fructose, fucose, etc.), and a combination thereof.
  • the osmolyte is added over and above its concentration in a component already present in the defined medium (e.g., a sugar is added over and above the concentration specified for a sugar component).
  • any other serum-free media containing at least about 90 ⁇ M ornithine (or containing a combination of at least about 100 ⁇ M ornithine plus at least about 200 ⁇ M putrescine) are hereinafter referred to as ornithine supplemented (“OS”) media.
  • the present invention provides a cell culture comprising a cell line expressing a protein of interest in an OS medium as described above.
  • the cell culture contains insulin, which can be added as a point-of-use ingredient to the media, or can be included in the media formulation.
  • the cell line comprises cells capable of producing a biotherapeutic protein.
  • cell lines that are routinely used to produce protein biotherapeutics include inter alia primary cells, BSC cells, HeLa cells, HepG2 cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK cells, BHK-21 cells, CHO cells, CHO-K1 cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 3T3 cells, 293 cells, RK cells, Per.C6 cells and chicken embryo cells.
  • the cell line is a CHO cell line or one or more of several specific CHO cell variants optimized for large-scale protein production, e.g., CHO-K1.
  • Cell culture or “culture” means the growth and propagation of cells outside of a multicellular organism or tissue. Suitable culture conditions for mammalian cells are known in the art. See e.g. Animal cell culture: A Practical Approach, D. Rickwood, ed., Oxford University Press, New York (1992). Mammalian cells may be cultured in suspension or while attached to a solid substrate. Fluidized bed bioreactors, hollow fiber bioreactors, roller bottles, shake flasks, or stirred tank bioreactors, with or without microcarriers, and operated in a batch, fed batch, continuous, semi-continuous, or perfusion mode are available for mammalian cell culture. Cell culture media or concentrated feed media may be added to the culture continuously or at intervals during the culture. For example, a culture may be fed once per day, every other day, every three days, or may be fed when the concentration of a specific medium component, which is being monitored, falls outside a desired range.
  • Animal cells such as CHO cells, may be cultured in small scale cultures, such as in 125 ml containers having about 25 ml of media, 250 ml containers having about 50 to 100 ml of media, 500 ml containers having about 100 to 200 ml of media.
  • the cultures can be large scale such as for example 1000 ml containers having about 300 to 1000 ml of media, 3000 ml containers having about 500 ml to 3000 ml of media, 8000 ml containers having about 2000 ml to 8000 ml of media, and 15000 ml containers having about 4000 ml to 15000 ml of media.
  • Cultures for manufacturing can contain 10,000 L of media or more.
  • Concentrated feed medium may be based on any cell culture media formulation.
  • Such a concentrated feed medium can contain most of the components of the cell culture medium at, for example, about 5 ⁇ , 6 ⁇ , 7 ⁇ , 8 ⁇ , 9 ⁇ , 10 ⁇ , 12 ⁇ , 14 ⁇ , 16 ⁇ , 20 ⁇ , 30 ⁇ , 50 ⁇ , 100 ⁇ , 200 ⁇ , 400 ⁇ , 600 ⁇ , 800 ⁇ , or even about 1000 ⁇ of their normal useful amount.
  • Concentrated feed media are often used in fed batch culture processes.
  • the cell culture media is supplemented with “point-of-use additions”, also known as additions, point-of-use ingredients, or point-of-use chemicals, during the course of cell growth or protein production.
  • Point-of-use additions include any one or more of a growth factor or other proteins, a buffer, an energy source, a salt, an amino acid, a metal, and a chelator. Other proteins include transferrin and albumin.
  • Growth factors which include cytokines and chemokines, are generally known in the art and are known to stimulate cell growth, or in some cases, cellular differentialtion.
  • a growth factor is usually a protein (e.g., insulin), a small peptide, or a steroid hormone, such as estrogen, DHEA, testosterone, and the like.
  • a growth factor may be a non-natural chemical that promotes cell proliferation or protein production, such as e.g., tetrahydrofolate (THF), methotrexate, and the like.
  • Non-limiting examples of protein and peptide growth factors include angiopoietins, bone morphogenetic proteins (BMPs), brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), erythropoietin (EPO), fibroblast growth factor (FGF), glial cell line-derived neurotrophic factor (GDNF), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), growth differentiation factor-9 (GDF9), hepatocyte growth factor (HGF), hepatoma-derived growth factor (HDGF), insulin, insulin-like growth factor (IGF), migration-stimulating factor, myostatin (GDF-8), nerve growth factor (NGF) and other neurotrophins, platelet-derived growth factor (PDGF), thrombopoietin (TPO), transforming growth factor alpha(TGF- ⁇ ), transforming growth factor beta(TGF- ⁇ ), tumor necrosis factor-al
  • the cell culture media is supplemented with the point-of-use addition growth factor insulin.
  • the concentration of insulin in the media i.e., the amount of insulin in the cell culture media after addition, is from about 0.1 ⁇ M to 10 ⁇ M.
  • One or more the point-of-use additions can also be included in the media formulation of some embodiments.
  • Buffers are generally known in the art. The invention is not restricted to any particular buffer or buffers, and any one of ordinary skill in the art can select an appropriate buffer or buffer system for use with a particular cell line producing a particular protein.
  • a point-of-use addition buffer is NaHCO 3 .
  • the point-of-use addition buffer comprises NaHCO 3 .
  • the buffer is HEPES.
  • the point-of-use addition energy source is glucose.
  • the glucose can be added to a concentration of about 1 to 20 mM in the media. In some cases, glucose can be added at high levels up to 10 g/L.
  • Chelators are likewise well known in the art of cell culture and protein production. Tetrasodium EDTA dehydrate and citrate are two common chelators used in the art, although other chelators may be employed in the practice of this invention.
  • a point-of-use addition chelator is tetrasodium EDTA dihydrate.
  • a point-of-use addition chelator is citrate, such as Na 3 C 6 H 5 O 7 .
  • the cell culture may be supplemented with one or more point-of-use addition amino acids, such as e.g., glutamine.
  • the cell culture media is supplemented with the point-of-use addition glutamine at a final concentration of about 1 mM to 13 mM.
  • point-of-use additions include one or more of various metal salts, such as salts of iron, nickel, zinc and copper.
  • the cell culture media is supplemented with any one or more of copper sulfate, zinc sulfate, ferric chlroide; and nickel sulfate.
  • the cell culture media is supplemented with any one or more or all of the following point-of-use additions: about 29.8 mM NaHCO3, about 2 mM glutamine, about 0.86 ⁇ M insulin, about 11.1 mM glucose, about 6.54 ⁇ M zinc sulfate, about 0.168 ⁇ M copper sulfate, about 75 ⁇ M ferric chloride, about 0.639 ⁇ M nickel sulfate, about 85 ⁇ M EDTA, and about 50 ⁇ M citrate.
  • the media is supplemented at intervals during cell culture according to a fed-batch process.
  • Fed-batch culturing is generally known in the art and employed to optimized protein production (see Y. M. Huang et al., Biotechnol Prog. 2010 September-October; 26(5): 1400-10).
  • Cell viability, viable cell density, and cell doubling are improved relative to cells grown in culture without ornithine or putrescine.
  • cells grown in OS media show a viability that is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least, 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, at least 100%, or at least 3-fold greater than the viability of similar or identical cells grown in non-OS media.
  • the doubling rate of viable mammalian cells in OS media is at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or at least 3-fold greater than the doubling rate of mammalian cells cultured in non-OS media.
  • the doubling rate of viable mammalian cells in OS media is about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% greater than the doubling rate of mammalian cells in non-OS media.
  • the doubling time of actively cycling mammalian cells is less than 30 hours, less than 29 hours, less than 28 hours, less than 27 hours, less than 26 hours, less than 25 hours, less than 24 hours, less than 23 hours, less than 22 hours, less than 21 hours, less than 20 hours, less than 19 hours, or less than 18 hours in OS media. In some embodiments, the doubling time of actively growing mammalian cells is less than 28 hours in OS media. In some embodiments, the doubling time of mammalian cells is about 27 ⁇ 1 hours, about 26 ⁇ 1 hours, about 25 ⁇ 1 hours, about 24 ⁇ 1 hours, about 23 ⁇ 1 hours, about 22 ⁇ 1 hours, or about 21 ⁇ 1 hours in OS media.
  • the doubling time of actively cycling mammalian cells is about 24 ⁇ 1 hours in OS media. In some embodiments, the doubling time of actively dividing cells cultured in OS media is at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, or at least 25% shorter than the doubling time of actively cycling cells cultured in a non-OS media.
  • the present invention provides methods of producing a protein, such as a therapeutically effective antibody or other biopharmaceutical drug substance, in a cell cultured in OS media.
  • the rate of production of protein by mammalian cells cultured in OS media is at least 5%, 10%, 15%, or 20% greater than the rate of production of protein by an identical mammalian cell cultured in non-OS media.
  • the rate of production of protein in cells cultured in OS media is at least 1 ⁇ g/cell/day (“PCD”), at least 2 PCD, at least 3 PCD, at least 4 PCD, at least 5 PCD, at least 6 PCD, at least 7 PCD, at least 8 PCD, at least 9 PCD, at least 10 PCD, at least 15 PCD, at least 20 PCD, at least 25 PCD, at least 30 PCD, at least 35 PCD, at least 40 PCD, at least 45 PCD, at least 50 PCD, at least 75 PCD, or at least 100 PCD.
  • PCD ⁇ g/cell/day
  • the protein production yield or titer which can be expressed in grams of protein product per liter of culture media, from cells cultured in OS media is at least 100 mg/L, at least 1 g/L, at least 1.2 g/L, at least 1.4 g/L, at least 1.6 g/L, at least 1.8 g/L, at least 2 g/L, at least 2.5 g/L, at least 3 g/L, at least, 3.5 g/L, at least 4 g/L, at least 4.5 g/L, at least 5 g/L, at least 5.5 g/L, at least 6 g/L, at least 6.5 g/L, at least 7 g/L, at least 7.5 g/L, at least 8 g/L, at least 8.5 g/L, at least 9 g/L, at least 9.5 g/L, at least 10 g/L, or at least 20 g/L.
  • the protein product is an antibody, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a multispecific antibody, a bispecific antibody, an antigen binding antibody fragment, a single chain antibody, a diabody, triabody or tetrabody, a Fab fragment or a F(ab′)2 fragment, an IgD antibody, an IgE antibody, an IgM antibody, an IgG antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody.
  • the antibody is an IgG1 antibody.
  • the antibody is an IgG2 antibody.
  • the antibody is an IgG4 antibody.
  • the protein of interest is a recombinant protein that contains an Fc moiety and another domain, (e.g., an Fc-fusion protein).
  • an Fc-fusion protein is a receptor Fc-fusion protein, which contains one or more of one or more extracellular domain(s) of a receptor coupled to an Fc moiety.
  • the Fc moiety comprises a hinge region followed by a CH2 and CH3 domain of an IgG.
  • the receptor Fc-fusion protein contains two or more distinct receptor chains that bind to either a single ligand or multiple ligands.
  • an Fc-fusion protein is a trap, such as for example an IL-1 trap (e.g., rilonacept, which contains the IL-1 RAcP ligand binding region fused to the II-1R1 extracellular region fused to Fc of hIgG1; see U.S. Pat. No. 6,927,004, which is herein incorporated by reference in its entirety), or a VEGF trap (e.g., aflibercept, which contains the Ig domain 2 of the VEGF receptor Flt1 fused to the Ig domain 3 of the VEGF receptor Flk1 fused to Fc of hIgG1; see U.S. Pat. Nos. 7,087,411 and 7,279,159).
  • IL-1 trap e.g., rilonacept, which contains the IL-1 RAcP ligand binding region fused to the II-1R1 extracellular region fused to Fc of hIgG1; see U.S. Pat. No.
  • the present invention is not limited to any particular type of cell for protein production.
  • Examples of cell types suitable for protein production include mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells.
  • the cells may be stem cells or recombinant cells transformed with a vector for recombinant gene expression, or cells transfected with a virus for producing viral products.
  • the cells may contain a recombinant heterologous polynucleotide construct that encodes a protein of interest. That construct can be an episome or it can be an element that is physically integrated into the genome of the cell.
  • the cells may also produce a protein of interest without having that protein encoded on a heterologous polypeptide construct.
  • the cell may naturally encode the protein of interest, such as a B-cell producing an antibody.
  • the cells may also be primary cells, such as chicken embryo cells, or primary cell lines.
  • useful cells include BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, chicken embryo cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, RK cells, Per.C6 cells and CHO cells.
  • the cell line is a CHO cell derviative, such as CHO-K1, CHO DUX B-11, CHO DG-44, Veggie-CHO, GS-CHO, S-CHO, or CHO Iec mutant lines.
  • the cell which is a CHO cell, ectopically expresses a protein.
  • the protein comprises an immunoglobulin heavy chain region, such as a CH1, CH2, or CH3 region.
  • the protein comprises a human or rodent immunoglobulin CH2 and CH3 region.
  • the protein comprises a human or rodent immunoglobulin CH1, CH2, and CH3 region.
  • the protein comprises a hinge region and a CH1, CH2, and CH3 region.
  • the protein comprises an immunoglobulin heavy chain variable domain.
  • the protein comprises an immunoglobulin light chain variable domain.
  • the protein comprises an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain.
  • the protein is an antibody, such as a human antibody, a rodent antibody, or a chimeric human/rodent antibody (e.g., human/mouse, human/rat, or human hamster).
  • a production phase can be conducted at any scale of culture, from individual flasks and shaker flasks or wave bags, to one-liter bioreactors, and to large scale industrial bioreactors.
  • a large scale process can be conducted in a volume of about 100 liters to 20,000 liters or more.
  • One or more of several means may be used to control protein production, such as temperature shift or chemical induction.
  • a growth phase may occur at a higher temperature than a production phase. For example, a growth phase may occur at a first temperature of about 35° C. to 38° C., and a production phase may occur at a second temperature of about 29° C. to 37° C., optionally from about 30° C. to 36° C. or from about 30° C. to 34° C.
  • inducers of protein production such as caffeine, butyrate, tamoxifen, estrogen, tetracycline, doxycycline, and hexamethylene bisacetamide (HMBA) may be added concurrent with, before, or after a temperature shift. If inducers are added after a temperature shift, they can be added from one hour to five days after the temperature shift, such as from one to two days after the temperature shift.
  • Production cell cultures may be run as continuous feed culture system, as in a chemostat (see C. Altamirano et al., Biotechnol Prog. 2001 November-December; 17(6):1032-41), or according to a fed-batch process (Huang, 2010).
  • the invention is useful for improving protein production via cell culture processes.
  • the cell lines used in the invention can be genetically engineered to express a polypeptide of commercial or scientific interest. Genetically engineering the cell line involves transfecting, transforming or transducing the cells with a recombinant polynucleotide molecule, or otherwise altering (e.g., by homologous recombination and gene activation or fusion of a recombinant cell with a non-recombinant cell) so as to cause the host cell to express a desired recombinant polypeptide.
  • Methods and vectors for genetically engineering cells or cell lines to express a polypeptide of interest are well known to those of skill in the art; for example, various techniques are illustrated in Current Protocols in Molecular Biology.
  • cell lines commonly used in the industry include VERO, BHK, HeLa, CVI (including Cos), MDCK, 293, 3T3, myeloma cell lines (e.g., NSO, NSI), PC12, WI38 cells, and Chinese hamster ovary (CHO) cells.
  • CHO cells are widely used for the production of complex recombinant proteins, such as cytokines, clotting factors, and antibodies (Brasel et al. (1996), Blood 88:2004-2012; Kaufman et al. (1988), J. Biol Chem 263:6352-6362; McKinnon et al. (1991), J Mol Endocrinol 6:231-239; Wood et al.
  • DHFR dihydrofolate reductase
  • the CHO cell lines are cell lines as described in U.S. Patent Application Publications No. 2010/0304436 A1, 2009/0162901 A1 and 2009/0137416 A1, and U.S. Pat. Nos. 7,455,988 B2, 7,435,553 B2, and 7,105,348 B2.
  • the invention is based, in part, on the discovery that addition of ornithine or a combination of ornithine and putrescine to serum free cell culture media results in increased cell growth, viability and polypeptide production from a recombinantly engineered animal cell line (or natural cell) expressing a protein of interest, thereby enhancing culture robustness, improving the yield of the polypeptide of interest.
  • a 250 mL shake flask was inoculated from a seed culture of a recombinant antibody producing cell line derived from CHO K1.
  • the inoculated cells were grown at 36.5° C. for seven days and fed glucose on days three and five.
  • Cells were grown in each of two separate chemically defined (hydrolysate-free and serum-free) media.
  • the first medium contained about 75 mM amino acids (Medium 1)
  • the second medium contained about 40 mM amino acids (Medium 2)
  • both formulations contained no more than 2.5 ⁇ M (0.4 mg/L) putrescine.
  • Another group of medium conditions was generated by adding soy hydrolysate at a concentration of 7.5 g/L to Medium 2.
  • each of the three control media about 593 ⁇ M ornithine (as 100 mg/L L-ornithine.HCl), or a combination of about 593 ⁇ M ornithine (as 100 mg/L L-ornithine.HCl) and about 714 ⁇ M putrescine (as 115 mg/L putrescine.2HCl) were added. Aliquots of 3 mL culture were removed on days 3, 5, and 7 and viable cell counts were conducted using trypan blue exclusion on a BioProfile FLEXTM instrument (Nova Biomedical). At day zero, all cultures contained 0.8 ⁇ 10 6 viable cells per mL.
  • the doubling time of a recombinant antibody producing cell line derived from CHO K1 cells in logarithmic growth phase was determined under various cell culture media conditions. Seed train cultures were passaged at 36.5° C. in 250 mL shaker flasks over a period of 14 days in each of three separate media: Medium 1, Medium 2, and Medium 2 containing soy hydrolysate (Medium 2+Soy). Aliquots of 1 mL were removed from each condition on Day 0 and at the time of seed train passage (every 2 or 3 days), and viable cell counts were conducted using trypan blue exclusion on a CDVTM instrument (Nova Biomedical).
  • Medium 1 was tested unsupplemented or supplemented with ornithine.HCl at 100 mg/L or both putrescine.2HCl at 115 mg/L and ornithine.HCl at 100 mg/L.
  • Medium 2 with low putrescine.2HCl (0.4 mg/L) was tested unsupplemented or supplemented with ornithine.HCl at 100 mg/L or both putrescine.2HCl at 115 mg/L and ornithine.HCl at 100 mg/L.
  • Tables 3 and 4 Ornithine supplementation, either with or without putrescine, to Medium 1 was required to achieve significant growth.
  • Supplementing hydrolysate free Medium 2 with ornithine or ornithine+putrescine decreased the cell doubling time by about 25% to 30%. Doubling times were also reduced to a lesser extent upon the addition of ornithine or ornithine+putrescine to hydrolysate containing Medium 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US14/211,245 2013-03-15 2014-03-14 Serum-Free Cell Culture Medium Abandoned US20140273095A1 (en)

Priority Applications (46)

Application Number Priority Date Filing Date Title
CN201480023485.4A CN105143444A (zh) 2013-03-15 2014-03-14 无血清细胞培养基
SG10202107444XA SG10202107444XA (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
JP2016502807A JP6781039B2 (ja) 2013-03-15 2014-03-14 無血清細胞培養培地
KR1020207028935A KR102229380B1 (ko) 2013-03-15 2014-03-14 무혈청 세포 배양 배지
IL300911A IL300911A (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
CA3135232A CA3135232A1 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
BR122020021864-9A BR122020021864B1 (pt) 2013-03-15 2014-03-14 Meio para cultura de células
US14/211,245 US20140273095A1 (en) 2013-03-15 2014-03-14 Serum-Free Cell Culture Medium
CA3238123A CA3238123A1 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
EA201591817A EA037568B1 (ru) 2013-03-15 2014-03-14 Не содержащая сыворотки среда для культивирования клеток и способы ее применения
KR1020157027270A KR102166166B1 (ko) 2013-03-15 2014-03-14 무혈청 세포 배양 배지
CA3188491A CA3188491A1 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
SG10201707153UA SG10201707153UA (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
SG11201507072TA SG11201507072TA (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
CA2906768A CA2906768C (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
KR1020247014487A KR20240065185A (ko) 2013-03-15 2014-03-14 무혈청 세포 배양 배지
CA3238121A CA3238121A1 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
EA202190326A EA202190326A3 (ru) 2013-03-15 2014-03-14 Не содержащая сыворотки среда для культивирования клеток
NZ711935A NZ711935B2 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
PCT/US2014/028501 WO2014144198A1 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
KR1020217021749A KR20210090732A (ko) 2013-03-15 2014-03-14 무혈청 세포 배양 배지
EA202191602A EA202191602A3 (ru) 2013-03-15 2014-03-14 Не содержащая сыворотки среда для культивирования клеток
KR1020227027409A KR20220116571A (ko) 2013-03-15 2014-03-14 무혈청 세포 배양 배지
MX2015013176A MX357977B (es) 2013-03-15 2014-03-14 Medio de cultivo celular libre de suero.
MYPI2015702985A MY175957A (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
KR1020217007530A KR102278316B1 (ko) 2013-03-15 2014-03-14 무혈청 세포 배양 배지
BR112015022682-5A BR112015022682B1 (pt) 2013-03-15 2014-03-14 Método para cultivar células e para produzir uma proteína
AU2014227804A AU2014227804B2 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
IL281515A IL281515B2 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium
IL241195A IL241195B (en) 2013-03-15 2015-09-06 Serum-free cell culture
MX2021001859A MX2021001859A (es) 2013-03-15 2015-09-15 Medio de cultivo celular libre de suero.
MX2021008627A MX2021008627A (es) 2013-03-15 2015-09-15 Medio de cultivo celular libre de suero.
HK16101075.8A HK1213289A1 (zh) 2013-03-15 2016-01-29 無血清細胞培養基
IL264499A IL264499A (en) 2013-03-15 2019-01-28 Serum-free culture medium
JP2019083625A JP6944969B2 (ja) 2013-03-15 2019-04-25 無血清細胞培養培地
AU2020200052A AU2020200052B2 (en) 2013-03-15 2020-01-03 Serum-free cell culture medium
US16/742,695 US11332771B2 (en) 2013-03-15 2020-01-14 Serum-free cell culture medium
US17/370,389 US11970724B2 (en) 2013-03-15 2021-07-08 Serum-free cell culture medium
AU2021205088A AU2021205088B2 (en) 2013-03-15 2021-07-15 Serum-free cell culture medium
JP2021132239A JP2021180682A (ja) 2013-03-15 2021-08-16 無血清細胞培養培地
IL289724A IL289724B2 (en) 2013-03-15 2022-01-10 Serum-free cell culture medium
US17/712,697 US20220228187A1 (en) 2013-03-15 2022-04-04 Serum-free cell culture medium
AU2022211862A AU2022211862A1 (en) 2013-03-15 2022-08-04 Serum-free cell culture medium
US17/882,224 US20220372436A1 (en) 2013-03-15 2022-08-05 Serum-free cell culture medium
JP2022145754A JP7429743B2 (ja) 2013-03-15 2022-09-14 無血清細胞培養培地
JP2023189068A JP2024001357A (ja) 2013-03-15 2023-11-06 無血清細胞培養培地

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790136P 2013-03-15 2013-03-15
US14/211,245 US20140273095A1 (en) 2013-03-15 2014-03-14 Serum-Free Cell Culture Medium

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/742,695 Continuation US11332771B2 (en) 2013-03-15 2020-01-14 Serum-free cell culture medium
US17/712,697 Continuation US20220228187A1 (en) 2013-03-15 2022-04-04 Serum-free cell culture medium

Publications (1)

Publication Number Publication Date
US20140273095A1 true US20140273095A1 (en) 2014-09-18

Family

ID=51528781

Family Applications (5)

Application Number Title Priority Date Filing Date
US14/211,245 Abandoned US20140273095A1 (en) 2013-03-15 2014-03-14 Serum-Free Cell Culture Medium
US16/742,695 Active US11332771B2 (en) 2013-03-15 2020-01-14 Serum-free cell culture medium
US17/370,389 Active US11970724B2 (en) 2013-03-15 2021-07-08 Serum-free cell culture medium
US17/712,697 Pending US20220228187A1 (en) 2013-03-15 2022-04-04 Serum-free cell culture medium
US17/882,224 Pending US20220372436A1 (en) 2013-03-15 2022-08-05 Serum-free cell culture medium

Family Applications After (4)

Application Number Title Priority Date Filing Date
US16/742,695 Active US11332771B2 (en) 2013-03-15 2020-01-14 Serum-free cell culture medium
US17/370,389 Active US11970724B2 (en) 2013-03-15 2021-07-08 Serum-free cell culture medium
US17/712,697 Pending US20220228187A1 (en) 2013-03-15 2022-04-04 Serum-free cell culture medium
US17/882,224 Pending US20220372436A1 (en) 2013-03-15 2022-08-05 Serum-free cell culture medium

Country Status (22)

Country Link
US (5) US20140273095A1 (ko)
EP (4) EP4159841A1 (ko)
JP (5) JP6781039B2 (ko)
KR (6) KR20210090732A (ko)
CN (2) CN105143444A (ko)
AR (1) AR095196A1 (ko)
AU (4) AU2014227804B2 (ko)
BR (2) BR112015022682B1 (ko)
CA (5) CA2906768C (ko)
DK (1) DK2970876T3 (ko)
EA (3) EA202191602A3 (ko)
ES (1) ES2682929T3 (ko)
HK (1) HK1213289A1 (ko)
HU (1) HUE040233T2 (ko)
IL (5) IL281515B2 (ko)
MX (3) MX357977B (ko)
MY (1) MY175957A (ko)
PL (1) PL2970876T3 (ko)
PT (1) PT2970876T (ko)
SG (3) SG10201707153UA (ko)
TW (4) TWI629359B (ko)
WO (1) WO2014144198A1 (ko)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017092841A1 (en) * 2015-12-03 2017-06-08 Merck Patent Gmbh Chemically defined media for the growth or detection of microorganisms
JP2018530344A (ja) * 2015-10-15 2018-10-18 アルテオジェン・インコーポレイテッド ＩｇＧ Ｆｃドメインを有する融合タンパク質の生産方法
WO2019135238A1 (en) * 2018-01-03 2019-07-11 Technion Research & Development Foundation Limited Naive pluripotent stem cell media
WO2020229584A1 (en) * 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US11053280B2 (en) 2019-12-06 2021-07-06 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11332771B2 (en) 2013-03-15 2022-05-17 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US20220213431A1 (en) * 2014-03-24 2022-07-07 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
WO2022159432A1 (en) * 2021-01-20 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
US11821001B2 (en) * 2019-04-23 2023-11-21 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
JP7495451B2 (ja) 2015-08-04 2024-06-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タウリン補足細胞培養培地およびその使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180047404A (ko) * 2016-10-31 2018-05-10 삼성바이오에피스 주식회사 세포 배양 배지에서 원치 않는 배양 부산물을 감소시키는 공정
CN108220334A (zh) * 2016-12-09 2018-06-29 上海迈泰君奥生物技术有限公司 无血清细胞培养基及高效表达重组蛋白质的方法
CN106635953B (zh) * 2016-12-13 2021-02-19 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
CA3067847A1 (en) * 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
CN108103003B (zh) * 2017-12-12 2021-03-05 四川百诺吉科技有限公司 一种适应pk-15全悬浮生长的无血清培养基及其制备方法和应用于pk-15细胞的全悬浮驯化方法
CN110438066B (zh) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用
WO2021150558A1 (en) 2020-01-21 2021-07-29 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
BR112023003273A2 (pt) 2020-08-31 2023-05-02 Regeneron Pharma Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
KR20220127465A (ko) 2021-03-11 2022-09-20 주식회사 만도 조향 제어 장치 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212778A1 (en) * 2006-02-14 2007-09-13 Genetix Limited Cell culture medium
WO2011079004A1 (en) * 2009-12-23 2011-06-30 Schering Corporation Cell line 3m

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
EP0082974B1 (en) 1981-12-24 1986-05-14 Asahi Kasei Kogyo Kabushiki Kaisha Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
DE3801236A1 (de) 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5529920A (en) 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
AU621972B2 (en) 1988-12-14 1992-03-26 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cell culture medium for human liver epithelial cell line
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5426699A (en) 1993-10-25 1995-06-20 Antec Corporation Method and apparatus for digitizing a scrambled analog video signal
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
EP0781294A1 (de) 1995-07-17 1997-07-02 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Metallhaltige ribonukleotidpolypeptide
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6043092A (en) 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6146847A (en) 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
AU2455199A (en) 1998-01-12 1999-07-26 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6589759B1 (en) 1999-03-30 2003-07-08 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
EP1544299B1 (en) * 1999-06-08 2008-12-17 Regeneron Pharmaceuticals, Inc. VEGF receptor chimeras for the treatment of eye disorders characterized by vascular permeability
CN1114619C (zh) * 1999-06-25 2003-07-16 中国科学院上海细胞生物学研究所 小鼠杂交瘤株Hepama－1分泌的肝癌鼠源单克隆抗体的制备方法
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1392859B1 (en) 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
ATE372688T1 (de) 2001-03-05 2007-09-15 Council Scient Ind Res Verfahren zur herstellung von proteinhydrolysate aus sojamehl
EP1321515A1 (en) * 2001-12-21 2003-06-25 Ingenium Pharmaceuticals AG Method of culturing cells
CN1180080C (zh) * 2002-01-18 2004-12-15 中国科学院上海细胞生物学研究所 一种改进的肝癌鼠源单克隆抗体的制备方法
DE60309238T2 (de) 2002-03-08 2007-06-06 Asml Netherlands B.V. Lithographische Maske, lithographischer Apparat und Verfahren zur Herstellung einer Vorrichtung
JP4817657B2 (ja) 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
PT1623019E (pt) 2003-05-15 2010-07-20 Wyeth Llc ALIMENTAÆO COM GLUCOSE DE MODO LIMITADO PARA CULTURA DE CéLULAS ANIMAIS
US7303694B2 (en) 2003-07-17 2007-12-04 Wisconsin Alumni Research Foundation Liquid crystals with reduced toxicity and applications thereof
US7462487B2 (en) 2003-09-18 2008-12-09 Raven Biotechnologies, Inc. Cell culture media
PL1767546T3 (pl) 2004-06-08 2012-07-31 Chengdu Kanghong Biotechnologies Co Ltd Hamujące angiogenezę białka chimeryczne i ich zastosowanie
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1812557A4 (en) 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
US8273553B2 (en) 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PT1974014T (pt) * 2006-01-04 2017-05-26 Baxalta Inc Meios de cultura celulares livres de oligopeptídeos
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PL2078071T3 (pl) * 2006-11-08 2015-07-31 Wyeth Llc Racjonalnie opracowane pożywki do hodowli komórek
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
ES2527297T3 (es) 2007-07-31 2015-01-22 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos para CD20 humano y método para utilizar los mismos
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CN100482786C (zh) * 2007-12-28 2009-04-29 天津百若克医药生物技术有限责任公司 一种人胚肾293细胞扩增无蛋白培养基
EP2250251B1 (en) * 2008-01-09 2017-11-22 Sartorius Stedim Cellca GmbH Improved culture media additive and process for using it
KR20110060911A (ko) * 2008-09-26 2011-06-08 쉐링 코포레이션 고 역가 항체 생산
CA2742107A1 (en) 2008-11-12 2010-05-20 Baxter International Inc. Method of producing serum-free insulin-free factor vii
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR101641526B1 (ko) 2009-06-02 2016-07-21 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
CN101603026B (zh) 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
KR101756354B1 (ko) * 2009-07-31 2017-07-26 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
PL3281636T3 (pl) 2010-02-24 2021-03-08 Chiesi Farmaceutici S.P.A. Sposób wytwarzania i oczyszczania rekombinowanej lizosomalnej alfa-mannozydazy
EP2563906B1 (en) 2010-04-26 2017-11-08 Novartis AG Process for cultivation of cho cells
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
ES2599412T3 (es) 2010-05-28 2017-02-01 F. Hoffmann-La Roche Ag Disminución del nivel de lactato y aumento de la producción de polipéptidos regulando por disminución la expresión de la lactato deshidrogenasa y de la piruvato deshidrogenasa quinasa
JP6138683B2 (ja) * 2010-07-08 2017-05-31 バクスアルタ ゲーエムベーハー 細胞培養による組換え型ａｄａｍｔｓ１３産生方法
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AU2011296702A1 (en) 2010-08-31 2013-03-21 Friesland Brands B.V. Culture medium for eukaryotic cells
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
EA034617B1 (ru) 2010-10-06 2020-02-27 Ридженерон Фармасьютикалз, Инк. Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r)
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
KR101903208B1 (ko) * 2010-12-28 2018-10-01 추가이 세이야쿠 가부시키가이샤 동물 세포의 배양 방법
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
EA033387B1 (ru) 2012-01-23 2019-10-31 Regeneron Pharma СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
JP6090735B2 (ja) 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
EP2843042B1 (en) 2012-04-25 2018-11-07 Riken Cell preparation containing myocardium-committed cell
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
IN2014DN10441A (ko) 2012-06-21 2015-08-21 Baxter Int
MX2015001550A (es) 2012-08-02 2015-05-11 Sanofi Sa Articulo de fabricacion que comprende aflibercept o ziv-aflibercept.
KR20150041662A (ko) 2012-08-13 2015-04-16 리제너론 파아마슈티컬스, 인크. Ｐｈ-의존적 결합 특성을 갖는 항-ｐｃｓｋ9 항체
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014066519A1 (en) 2012-10-23 2014-05-01 Genzyme Corporation Perfusion culturing methods and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
MX367025B (es) 2013-02-22 2019-08-02 Genzyme Corp Metodos de cultivo por perfusion con microportadores y usos de los mismos.
CN105209625B (zh) 2013-03-12 2019-03-29 Cmc依科斯生技制品公司 使用杂合chef1启动子的改善重组蛋白表达
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EP2971035B1 (en) 2013-03-14 2019-06-12 MedImmune, LLC Recombinant polypeptide production
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US20160237400A1 (en) 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
CN105007929B (zh) 2013-03-15 2019-05-10 瑞泽恩制药公司 Il-33拮抗剂和其用途
WO2014191240A1 (en) 2013-05-29 2014-12-04 F. Hoffmann-La Roche Ag Quantitative control of sialylation
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
CN112481337A (zh) 2014-01-13 2021-03-12 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EP3126388B1 (en) 2014-03-11 2019-05-08 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibodies and uses thereof
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
RU2020103811A (ru) 2014-05-05 2020-02-18 Регенерон Фармасьютикалз, Инк. Гуманизированные животные по с5 и с3
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
TWI654202B (zh) 2014-05-27 2019-03-21 中央研究院 增進抗體功效之通用糖型之組合物及方法
MA40021A (fr) 2014-06-03 2015-12-10 Lupin Ltd Processus de culture cellulaire destiné à produire une protéine
KR20170062466A (ko) 2014-09-16 2017-06-07 리제너론 파마슈티칼스 인코포레이티드 항-글루카곤 항체 및 그것의 사용
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
CA2996643A1 (en) 2015-04-01 2016-10-06 Boehringer Ingelheim International Gmbh Cell culture medium
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TW202140776A (zh) 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
CA3067847A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212778A1 (en) * 2006-02-14 2007-09-13 Genetix Limited Cell culture medium
WO2011079004A1 (en) * 2009-12-23 2011-06-30 Schering Corporation Cell line 3m

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11332771B2 (en) 2013-03-15 2022-05-17 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US11970724B2 (en) 2013-03-15 2024-04-30 Regeneron Pharmaceuticals, Inc. Serum-free cell culture medium
US20220213431A1 (en) * 2014-03-24 2022-07-07 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
JP7198868B2 (ja) 2015-08-04 2023-01-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タウリン補足細胞培養培地およびその使用
US11312936B2 (en) 2015-08-04 2022-04-26 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
JP2022162157A (ja) * 2015-08-04 2022-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タウリン補足細胞培養培地およびその使用
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
JP7495451B2 (ja) 2015-08-04 2024-06-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タウリン補足細胞培養培地およびその使用
JP2021112215A (ja) * 2015-08-04 2021-08-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. タウリン補足細胞培養培地およびその使用
JP2020114266A (ja) * 2015-10-15 2020-07-30 アルテオジェン・インコーポレイテッド ＩｇＧ Ｆｃドメインを有する融合タンパク質の生産方法
JP2018530344A (ja) * 2015-10-15 2018-10-18 アルテオジェン・インコーポレイテッド ＩｇＧ Ｆｃドメインを有する融合タンパク質の生産方法
WO2017092841A1 (en) * 2015-12-03 2017-06-08 Merck Patent Gmbh Chemically defined media for the growth or detection of microorganisms
WO2019135238A1 (en) * 2018-01-03 2019-07-11 Technion Research & Development Foundation Limited Naive pluripotent stem cell media
US11821001B2 (en) * 2019-04-23 2023-11-21 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
WO2020229584A1 (en) * 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
US11535663B2 (en) 2019-12-06 2022-12-27 Regeneron Pharmaceuticals, Inc. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US11505594B2 (en) 2019-12-06 2022-11-22 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11299532B2 (en) 2019-12-06 2022-04-12 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11286290B2 (en) 2019-12-06 2022-03-29 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11186625B2 (en) 2019-12-06 2021-11-30 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11053280B2 (en) 2019-12-06 2021-07-06 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11407813B2 (en) 2019-12-06 2022-08-09 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11440950B2 (en) 2019-12-06 2022-09-13 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11459374B2 (en) 2019-12-06 2022-10-04 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11459373B2 (en) 2019-12-06 2022-10-04 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11472861B2 (en) 2019-12-06 2022-10-18 Regeneron Pharmaceuticals, Inc. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US11180540B2 (en) 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11485770B2 (en) 2019-12-06 2022-11-01 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11306135B2 (en) 2019-12-06 2022-04-19 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11505593B2 (en) 2019-12-06 2022-11-22 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11174283B2 (en) 2019-12-06 2021-11-16 Regeneran Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11542317B1 (en) 2019-12-06 2023-01-03 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11104715B2 (en) 2019-12-06 2021-08-31 Regeneran Pharmaceuticals, Inc. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
US11548932B2 (en) 2019-12-06 2023-01-10 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11649273B2 (en) 2019-12-06 2023-05-16 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11732025B2 (en) 2019-12-06 2023-08-22 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11753459B2 (en) 2019-12-06 2023-09-12 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11098311B2 (en) 2019-12-06 2021-08-24 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
US11098112B2 (en) 2019-12-06 2021-08-24 Regeneron Pharmnaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2022159432A1 (en) * 2021-01-20 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture

Also Published As

Publication number Publication date
IL289724B1 (en) 2023-04-01
HK1213289A1 (zh) 2016-06-30
TWI629359B (zh) 2018-07-11
IL289724A (en) 2022-03-01
MX2021001859A (es) 2021-04-19
TW201502273A (zh) 2015-01-16
US20200149081A1 (en) 2020-05-14
EP3378932A1 (en) 2018-09-26
AU2022211862A1 (en) 2022-08-25
US20220372436A1 (en) 2022-11-24
JP7429743B2 (ja) 2024-02-08
JP2019150037A (ja) 2019-09-12
KR20150128785A (ko) 2015-11-18
HUE040233T2 (hu) 2019-02-28
KR102278316B1 (ko) 2021-07-19
EP3919611A1 (en) 2021-12-08
PT2970876T (pt) 2018-10-22
CA2906768A1 (en) 2014-09-18
AU2021205088B2 (en) 2022-09-22
KR20240065185A (ko) 2024-05-14
EA202190326A3 (ru) 2021-09-30
IL289724B2 (en) 2023-08-01
WO2014144198A1 (en) 2014-09-18
NZ711935A (en) 2021-04-30
EP2970876A1 (en) 2016-01-20
EA202191602A2 (ru) 2021-08-31
JP2022172390A (ja) 2022-11-15
AU2014227804A1 (en) 2015-09-24
KR20210031778A (ko) 2021-03-22
KR20210090732A (ko) 2021-07-20
MX357977B (es) 2018-08-01
AU2021205088A1 (en) 2021-08-12
IL241195B (en) 2019-05-30
AU2020200052B2 (en) 2023-01-19
CA2906768C (en) 2022-08-30
MY175957A (en) 2020-07-16
AR095196A1 (es) 2015-09-30
JP2021180682A (ja) 2021-11-25
SG10202107444XA (en) 2021-08-30
SG10201707153UA (en) 2017-10-30
CN113481148A (zh) 2021-10-08
JP6944969B2 (ja) 2021-10-06
IL281515A (en) 2021-04-29
BR112015022682B1 (pt) 2023-03-28
IL281515B1 (en) 2024-01-01
EP2970876B1 (en) 2018-07-11
KR102166166B1 (ko) 2020-10-15
IL241195A0 (en) 2015-11-30
KR102229380B1 (ko) 2021-03-18
JP2016514452A (ja) 2016-05-23
TWI782295B (zh) 2022-11-01
EA201591817A1 (ru) 2016-05-31
JP2024001357A (ja) 2024-01-09
CA3135232A1 (en) 2014-09-18
TW201835325A (zh) 2018-10-01
IL300911A (en) 2023-04-01
BR122020021864B1 (pt) 2022-09-20
KR20200119894A (ko) 2020-10-20
ES2682929T3 (es) 2018-09-24
KR20220116571A (ko) 2022-08-23
MX2021008627A (es) 2022-06-14
DK2970876T3 (en) 2018-08-13
TW202041672A (zh) 2020-11-16
EA202191602A3 (ru) 2021-12-31
AU2014227804B2 (en) 2020-01-30
SG11201507072TA (en) 2015-10-29
TW202325723A (zh) 2023-07-01
TWI701333B (zh) 2020-08-11
EA037568B1 (ru) 2021-04-15
EP4159841A1 (en) 2023-04-05
IL281515B2 (en) 2024-05-01
IL264499A (en) 2019-02-28
US11970724B2 (en) 2024-04-30
PL2970876T3 (pl) 2018-11-30
CA3238123A1 (en) 2014-09-18
JP6781039B2 (ja) 2020-11-04
MX2015013176A (es) 2016-04-07
BR112015022682A2 (pt) 2017-07-18
AU2020200052A1 (en) 2020-01-30
CA3238121A1 (en) 2014-09-18
EA202190326A2 (ru) 2021-05-31
US20210332402A1 (en) 2021-10-28
US20220228187A1 (en) 2022-07-21
CA3188491A1 (en) 2014-09-18
US11332771B2 (en) 2022-05-17
CN105143444A (zh) 2015-12-09

Similar Documents

Publication Publication Date Title
US11970724B2 (en) Serum-free cell culture medium
NZ711935B2 (en) Serum-free cell culture medium
EA044302B1 (ru) Не содержащая сыворотки среда для культивирования клеток
EA045169B1 (ru) Не содержащая сыворотки среда для культивирования клеток

Legal Events

Date Code Title Description
AS Assignment

Owner name: REGENERON PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OSHODI, SHADIA ABIKE;JOHNSON, AMY S.;LAWRENCE, SHAWN M.;SIGNING DATES FROM 20140129 TO 20140130;REEL/FRAME:033049/0372

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION